Genmab — December 2020
-
Dele af konklusionen: "Genmab is a long-term-accumulate kind of stock. It will have ups and downs, but every down is an opportunity because its pipeline is never-ending." og "Its basic expertise is in antibody technology, which it has expanded to include bsAb (bi-specific mAb) and other variants and drug conjugates."These will continue to run through trials and come to the market, and eventually, we will have another DARZALEX level product."
-
Sluttende med: "So there's really no end to it, and no long-term negatives in this well-managed company. Although current prices are high, if the stock falls on an adverse ruling in the JNJ case, I am buying because even DARZALEX is just one part of the Genmab story, and I am buying the entire story."
-
Og så Tue Østergaard i Børsen, Genmab måske bedste selskab og bedst ledede selskab i Danmark
https://borsen.dk/nyheder/investor/ny-optur-i-2021-disse-aktier-skal-du-have-i-portefoljen -
Hører også Tue blive hængende i vækstsegmentet modsat mange andre, ex. L.
Tvede, som vil gå mod value -
Genmab is a long-term-accumulate kind of stock. It will have ups and downs, but every down is an opportunity because its pipeline is never-ending https://newsfilter.io/articles/genmab-an-european-rd-behemoth-with-long-term-potential-8e3d1f6aad9d5df5fb9c741d17c8644c
-
God morgen.
-
Aktier/tendens: Udsigt til positiv åbning - ratenyt kan løfte Mærsk: https://www.proinvestor.com/investornyt/670673/aktier-tendens-udsigt-til-positiv-abning-ratenyt-kan-lofte-maersk
-
Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations https://www.businesswire.com/news/home/20201228005043/en/Janssen-Submits-European-Marketing-Authorisation-Application-for-Amivantamab-for-the-Treatment-of-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer-with-EGFR-Exon-20-Insertion-Mutations/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhBsNpnJw7dvSfTyni
-
Australia - From 1 January 2021, Darzalex
(daratumumab) will be listed for the first time in combination with bortezomib and dexamethasone, as a second-line treatment for patients with multiple myeloma https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/pbs-listings-bring-greater-hope-in-fight-against-multiple-myeloma-and-severe-psoriasis -
yes, and outcomes for these patients are very poor. Filing wasn't really such a surprise; they already flagged that they would. With FDA Breakthrough Therapy Designation in march, they submitted FDA BLA early this month , and recommendation on the request for accelerated assessment was on CHMP agenda this month
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind